EyePoint Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) said management will participate in four investor events in March 2026: TD Cowen (March 3), Barclays (March 10), Jefferies Biotech on the Beach (March 11) and RBC Virtual Ophthalmology (March 25).

A live webcast and archived replay will be available via the company’s Investors website.

News Market Reaction – EYPT

-0.12%

2 alerts

-0.12% News Effect

-$2M Valuation Impact

$1.47B Market Cap

0.0x Rel. Volume

On the day this news was published, EYPT declined 0.12%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $1.47B at that time.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:

• TD Cowen 46^th Annual Health Care Conference
  Forum: Fireside Chat
  Date: March 3, 2026
  Time: 2:30 p.m. ET
  
• Barclays 28^th Annual Global Healthcare Conference 2026
  Forum: 1x1 Investor Meetings
  Date: March 10, 2026
  
• Jefferies Biotech on the Beach Summit
  Forum: 1x1 Investor Meetings
  Date: March 11, 2026
  
• RBC Capital Markets Virtual Ophthalmology Conference
  Forum: Fireside Chat
  Date: March 25, 2026

A webcast and subsequent archived replay of the presentations may be accessed via the Investors section of the Company website at www.eyepoint.bio.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Green Room Communications 
Direct: 850-384-2833
EyePointMedia@grcomms.com

FAQ

When will EyePoint (EYPT) present at the TD Cowen Health Care Conference in 2026?

EyePoint will present a fireside chat on March 3, 2026 at 2:30 p.m. ET. According to the company, a webcast and archived replay will be available via the Investors section of the company website.

What investor events will EyePoint (EYPT) attend in March 2026?

EyePoint will attend TD Cowen, Barclays, Jefferies Biotech on the Beach, and RBC Virtual Ophthalmology in March 2026. According to the company, management will participate in fireside chats and 1x1 investor meetings at these events.

How can investors watch EyePoint (EYPT) presentations from March 2026 conferences?

Investors can view a live webcast and archived replay via the company Investors website. According to the company, recordings of the March presentations will be posted for later access on the site.

Will EyePoint (EYPT) hold one-on-one investor meetings at the Barclays and Jefferies events?

Yes, EyePoint scheduled 1x1 investor meetings at Barclays on March 10 and Jefferies on March 11, 2026. According to the company, management will be available for individual investor discussions at those events.

What format will EyePoint (EYPT) use at the RBC Virtual Ophthalmology Conference on March 25, 2026?

EyePoint will appear in a fireside chat format at the RBC Virtual Ophthalmology Conference on March 25, 2026. According to the company, the session will be webcast and an archived replay will be posted on the Investors website.